Skip header and navigation

1 records – page 1 of 1.

Evaluation of thiophosphoric acid alkaloid derivatives from Chelidonium majus L. ("Ukrain") as an immunostimulant in patients with various carcinomas.

https://arctichealth.org/en/permalink/ahliterature25022
Source
Drugs Exp Clin Res. 1991;17(2):139-43
Publication Type
Article
Date
1991
Author
J W Nowicky
A. Staniszewski
W. Zbroja-Sontag
B. Slesak
W. Nowicky
W. Hiesmayr
Author Affiliation
Ukrainian Anti-Cancer Institute, Vienna, Austria.
Source
Drugs Exp Clin Res. 1991;17(2):139-43
Date
1991
Language
English
Publication Type
Article
Keywords
Acute-Phase Proteins - analysis
Adjuvants, Immunologic
Adult
Aged
Alkaloids - therapeutic use
B-Lymphocytes - immunology
Complement System Proteins - analysis
Drug Interactions
Female
Humans
Immunoglobulins - analysis
Injections, Intravenous
Male
Middle Aged
Neoplasms - drug therapy - immunology
T-Lymphocyte Subsets - immunology
T-Lymphocytes, Regulatory
Abstract
This paper summarizes the preliminary results of two independent clinical trials conducted with the preparation "Ukrain", containing thiophosphoric acid alkaloid derivatives from the plant Chelidonium majus L. (greater celandine), in order to investigate whether it has immunopotentiating properties in cancer patients. A total of twenty-seven patients with various malignancies were treated with "Ukrain" given intravenously in a dose of 10 mg every three days. In all patients the cellular and humoral immune response was studied. There was an increase in both total T-cells and T-helper lymphocytes, a decrease in T-suppressor cells, and normalization of the helper/suppressor (HIS) ratio. A significant increase in erythrocyte-rosette-forming T-cells and NK cells was also demonstrated. Serum immunoglobulin levels, complement components (C3 and C4), and acute phase proteins were not significantly enhanced. Restoration of cellular immunity was accompanied by an improvement in the patients' performance status and in the clinical course of the disease. The treatment was generally well tolerated. The present study shows that some therapeutic benefit from the use of Chelidonium majus ("Ukrain") as an immunostimulant in cancer patients can be achieved.
PubMed ID
1713821 View in PubMed
Less detail